Monoamine Oxidase Inhibitors (MAOIs) Market Analysis By Types (MAO-A Inhibitor, MAO-B Inhibitor), By Drugs (Isocarboxazid, Phenelzine, Tranylcypromine, Others), By Disorder Type (Parkinson’s Disease, Depression, Anxiety, Others), By End Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) & Forecast
- PUBLISHED ON
- 4/28/2023
- NO OF PAGES
- 286
- CATEGORY
- Healthcare & Life Sciences
Monoamine oxidase inhibitors (MAOIs) are a class of drugs used primarily as antidepressants. They work by inhibiting the activity of the enzyme monoamine oxidase, which breaks down neurotransmitters such as serotonin, dopamine, and norepinephrine. This leads to an increase in the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression.
The market for MAOIs is relatively small compared to other antidepressant classes such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). This is due in part to the fact that MAOIs have a higher risk of side effects and drug interactions than other antidepressants.
There are currently only a few MAOIs on the market, including:
1. Isocarboxazid (Marplan)
2. Phenelzine (Nardil)
3. Tranylcypromine (Parnate)
These drugs are primarily used in cases of depression that have not responded to other treatments, or in cases where other treatments are not appropriate. MAOIs are also sometimes used to treat other conditions such as anxiety, Parkinson's disease, and borderline personality disorder.
Despite their relatively small market share, MAOIs remain an important option for patients with treatment-resistant depression. Ongoing research is focused on developing new MAOIs with fewer side effects and drug interactions, as well as exploring the potential of combining MAOIs with other medications to enhance their efficacy.
Report Scope
Report Attributes | Description |
Market Size in 2022 | USD 236 Million |
Market Forecast in 2032 | USD 324 Million |
CAGR % 2023-2031 | 5.3% |
Base Year | 2022 |
Historic Data | 2019-2021 |
Forecast Period | 2023-2031 |
Report USP | Production, Consumption, company share, company heatmap, company production capacity, growth factors and more |
Segments Covered | By Type, By Drugs, By Disorder Type, By End-user, By Distribution Channel |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Takeda Pharmaceutical Company Limited, Mylan N.V., GlaxoSmithKline plc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eli Lilly and Company, OrchidPharma Ltd., Validus Pharmaceuticals LLC, INDOCO REMEDIES LTD., Teikoku Pharma USA, Inc., H. Lundbeck A/S, Alliance Pharma PLC, Solvay, Cipla Inc, Allergan, SHIONOGI & Co., Ltd, BioSyent Inc., Glenmark Pharmaceuticals Limited, AstraZeneca, Johnson & Johnson Private Limited, Gedeon Richter., Luye Pharma Group, and Bristol-Myers Squibb |
Segment Overview
Monoamine oxidase inhibitors (MAOIs) are a class of medications used primarily to treat depression, anxiety, and Parkinson's disease. These drugs work by inhibiting the activity of the enzyme monoamine oxidase, which breaks down monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine. By inhibiting the breakdown of these neurotransmitters, MAOIs increase their levels in the brain, which can alleviate symptoms of depression and anxiety, and improve motor symptoms in Parkinson's disease.
The market for MAOIs is relatively small compared to other classes of antidepressants, as MAOIs are considered second-line treatments due to their potential side effects and interactions with other drugs and certain foods. However, there are several companies that manufacture and market MAOIs, including Pfizer, Novartis, and Mylan. These companies offer different formulations of MAOIs, such as tablets, capsules, and patches.
The market for MAOIs is segmented by indication, with the majority of sales coming from the depression and anxiety market. In recent years, there has been a growing interest in using MAOIs for the treatment of other conditions, such as borderline personality disorder and post-traumatic stress disorder. However, these indications are not yet approved by regulatory agencies in many countries.
The market for MAOIs is also segmented by geography, with the largest markets being North America and Europe. In these regions, MAOIs are primarily prescribed by psychiatrists and neurologists. In developing countries, MAOIs are less commonly used due to their higher cost and limited availability.
Geographical Overview
The market for monoamine oxidase inhibitors (MAOIs) varies by geography, with different regions having varying levels of usage and availability of these medications. Here is a brief overview of the MAOI market by geography:
North America: MAOIs are not commonly prescribed in North America and have been largely replaced by newer antidepressant medications such as SSRIs and SNRIs. However, they are still occasionally used for treatment-resistant depression or anxiety disorders.
Europe: MAOIs are more commonly used in Europe, particularly in France and the United Kingdom. They are often prescribed for atypical depression, anxiety disorders, and eating disorders.
Asia: MAOIs are still commonly used in some parts of Asia, particularly in China and Japan. They are often used for depression and anxiety disorders.
Latin America: MAOIs are less commonly used in Latin America, where they have largely been replaced by newer antidepressant medications.
Overall, the market for MAOIs is relatively small compared to other classes of antidepressant medications, and their usage has declined over time due to concerns about interactions with certain foods and other medications, as well as the availability of newer and often more effective treatments.
COVID Impact
Monoamine oxidase inhibitors (MAOIs) are a type of antidepressant medication used to treat depression and anxiety disorders. The COVID-19 pandemic has had an impact on the global pharmaceutical industry, including the market for MAOIs.
The COVID-19 pandemic has disrupted the global supply chain for pharmaceutical products, including MAOIs. Manufacturing and distribution of these medications have been affected due to lockdowns, travel restrictions, and supply chain disruptions. This has led to shortages of MAOIs in some regions, and increased prices in others.
Additionally, the pandemic has led to an increase in mental health issues, including depression and anxiety, which has driven demand for antidepressant medications like MAOIs. However, the pandemic has also caused economic uncertainty and job loss, which has led some people to avoid seeking treatment due to financial concerns.
Overall, the impact of COVID-19 on the MAOI market has been mixed, with increased demand and supply chain disruptions leading to shortages and higher prices in some regions. The long-term effects of the pandemic on the MAOI market remain to be seen, as the global pharmaceutical industry continues to adapt to the ongoing pandemic.
Competitive Analysis
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that are used to treat various psychiatric and neurological conditions, such as depression, anxiety disorders, and Parkinson's disease. MAOIs work by inhibiting the activity of the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters such as dopamine, serotonin, and norepinephrine.
Currently, there are several MAOIs available on the market, including phenelzine, tranylcypromine, and isocarboxazid. These drugs are generally used as second or third-line treatments for depression or anxiety disorders when other treatments have been ineffective.
One of the main challenges facing the MAOI market is the potential for serious side effects and drug interactions. MAOIs can interact with a wide range of foods and medications, leading to potentially life-threatening hypertensive crises. As a result, these drugs are generally only prescribed by psychiatrists or neurologists who have specialized training in their use.
Despite these challenges, the MAOI market remains relatively stable, with several companies producing and marketing these drugs. In addition, there is ongoing research aimed at developing new MAOIs that may be more effective and have fewer side effects than existing drugs.
Overall, the key to remaining competitive in the MAOI market is to stay up-to-date on the latest research and developments in the field, and to have specialized expertise in the use of these drugs. Companies that are able to develop new and innovative MAOIs that address the limitations of existing drugs will likely have a significant advantage in this market. Additionally, companies that are able to develop strategies for managing the potential side effects and drug interactions associated with MAOIs may also be well-positioned for success.
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $4250
Only Four Thousand Two Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $5250
Only Five Thousand Two Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $6250
Only Six Thousand Two Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI